U.S. markets close in 2 hours 14 minutes
  • S&P 500

    3,669.91
    +0.90 (+0.02%)
     
  • Dow 30

    30,003.30
    +119.51 (+0.40%)
     
  • Nasdaq

    12,396.43
    +47.06 (+0.38%)
     
  • Russell 2000

    1,859.34
    +21.31 (+1.16%)
     
  • Crude Oil

    45.73
    +0.45 (+0.99%)
     
  • Gold

    1,840.20
    +10.00 (+0.55%)
     
  • Silver

    24.09
    +0.01 (+0.06%)
     
  • EUR/USD

    1.2143
    +0.0028 (+0.23%)
     
  • 10-Yr Bond

    0.9210
    -0.0270 (-2.85%)
     
  • GBP/USD

    1.3474
    +0.0098 (+0.73%)
     
  • USD/JPY

    103.9060
    -0.5180 (-0.50%)
     
  • BTC-USD

    19,364.46
    +415.56 (+2.19%)
     
  • CMC Crypto 200

    380.86
    +6.45 (+1.72%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

What Is The Ownership Structure Like For American Renal Associates Holdings, Inc. (NYSE:ARA)?

Simply Wall St
·5 min read

If you want to know who really controls American Renal Associates Holdings, Inc. (NYSE:ARA), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

American Renal Associates Holdings is a smaller company with a market capitalization of US$397m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about American Renal Associates Holdings.

Check out our latest analysis for American Renal Associates Holdings

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About American Renal Associates Holdings?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

American Renal Associates Holdings already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at American Renal Associates Holdings' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in American Renal Associates Holdings. Centerbridge Capital Partners LP is currently the largest shareholder, with 49% of shares outstanding. Van Berkom and Associates Inc. is the second largest shareholder owning 8.3% of common stock, and Joseph Carlucci holds about 3.6% of the company stock. Joseph Carlucci, who is the third-largest shareholder, also happens to hold the title of Chairman of the Board.

A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 57% stake.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of American Renal Associates Holdings

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Shareholders would probably be interested to learn that insiders own shares in American Renal Associates Holdings, Inc.. It has a market capitalization of just US$397m, and insiders have US$34m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public holds a 11% stake in American Renal Associates Holdings. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 49%, private equity firms could influence the American Renal Associates Holdings board. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 3 warning signs we've spotted with American Renal Associates Holdings .

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.